FDA approves 1st biosimilar to Perjeta, Poherdy, for HER2-positive breast cancer treatment, enabling pharmacy-level substitution under state law.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback